Previous Close | 465.7 |
1-Year Change | 35.77% |
6-Months Change | 4.6% |
3-Months Change | -4.58% |
Moving Avg (50d) | 476.39 |
Moving Avg (200d) | 453.57 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 120.1B |
Beta (3-Years) | 0.6 |
Revenue Growth (ttm) | 10.96% |
Net Profit Margin (ttm) | 35.94% |
Return On Assets (ttm) | 15.97% |
EPS (ttm) | 13.32 |
PE Ratio (ttm) | 34.96 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England. Wikipedia